tradingkey.logo
tradingkey.logo
Buscar

ARS Pharmaceuticals Inc

SPRY
Añadir a la lista de seguimiento
8.560USD
+0.620+7.81%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
850.01MCap. mercado
PérdidaP/E TTM

Más Datos de ARS Pharmaceuticals Inc Compañía

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Información de ARS Pharmaceuticals Inc

Símbolo de cotizaciónSPRY
Nombre de la empresaARS Pharmaceuticals Inc
Fecha de salida a bolsaDec 04, 2020
Director ejecutivoLowenthal (Richard E)
Número de empleados155
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 04
Dirección11682 El Camino Real, Suite 300
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92130
Teléfono18587719307
Sitio Webhttps://ars-pharma.com/
Símbolo de cotizaciónSPRY
Fecha de salida a bolsaDec 04, 2020
Director ejecutivoLowenthal (Richard E)

Ejecutivos de ARS Pharmaceuticals Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Saqib Islam, J.D.
Mr. Saqib Islam, J.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric Karas
Mr. Eric Karas
Chief Commercial Officer
Chief Commercial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de ARS Pharmaceuticals Inc?

Los cinco principales accionistas de ARS Pharmaceuticals Inc son: Mr. Richard E. Lowenthal

¿Cuántas instituciones poseen acciones de ARS Pharmaceuticals Inc (SPRY)?

A fecha de 2026Q1, 412 instituciones poseen acciones de ARS Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 96.79M, lo que representa el 97.47% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -8902286.00.